Tim Anderson
Stock Analyst at B of A Securities
(3.44)
# 743
Out of 4,805 analysts
31
Total ratings
55.56%
Success rate
2.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Maintains: Buy | $22 → $26 | $7.79 | +233.76% | 2 | Mar 27, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $159 → $171 | $150.97 | +13.27% | 4 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $105.25 | +19.71% | 2 | Mar 5, 2025 | |
| AMGN Amgen | Maintains: Underperform | $275 → $294 | $291.09 | +1.00% | 4 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $179.84 | +24.00% | 5 | Mar 4, 2025 | |
| MTSR Metsera | Initiates: Buy | $38 | $15.27 | +148.85% | 1 | Feb 25, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $26.67 | +27.48% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $81.91 | +36.74% | 4 | Feb 5, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $22.49 | +28.95% | 1 | Dec 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Reinstates: Neutral | $63 | $53.74 | +17.23% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $120.49 | +47.73% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $565 | $576.72 | -2.03% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $753.71 | +32.28% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $103.85 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $66.76 | - | 1 | Sep 22, 2017 |
Aardvark Therapeutics
Mar 27, 2025
Maintains: Buy
Price Target: $22 → $26
Current: $7.79
Upside: +233.76%
Johnson & Johnson
Mar 5, 2025
Maintains: Neutral
Price Target: $159 → $171
Current: $150.97
Upside: +13.27%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $105.25
Upside: +19.71%
Amgen
Mar 5, 2025
Maintains: Underperform
Price Target: $275 → $294
Current: $291.09
Upside: +1.00%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $179.84
Upside: +24.00%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $15.27
Upside: +148.85%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $26.67
Upside: +27.48%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $81.91
Upside: +36.74%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $22.49
Upside: +28.95%
Bristol-Myers Squibb Company
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $53.74
Upside: +17.23%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $120.49
Upside: +47.73%
Dec 10, 2024
Reinstates: Underperform
Price Target: $565
Current: $576.72
Upside: -2.03%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $753.71
Upside: +32.28%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $103.85
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $66.76
Upside: -